EGFR and metastatic colorectal cancer: Moreover, our data may shape our ideas about re-sensitizing RAS mutant tumors toward EGFR inhibition and opens up new perspectives for designing more resistance preventive treatment approaches such as drug holiday concepts for patients with metastatic colorectal cancer.